916450-83-4Relevant academic research and scientific papers
Biaryl substituted hydantoin compounds as TACE inhibitors
Yu, Wensheng,Tong, Ling,Kim, Seong Heon,Wong, Michael K.C.,Chen, Lei,Yang, De-Yi,Shankar, Bandarpalle B.,Lavey, Brian J.,Zhou, Guowei,Kosinski, Aneta,Rizvi, Razia,Li, Dansu,Feltz, Robert J.,Piwinski, John J.,Rosner, Kristin E.,Shih, Neng-Yang,Siddiqui, M. Arshad,Guo, Zhuyan,Orth, Peter,Shah, Himanshu,Sun, Jing,Umland, Shelby,Lundell, Daniel J.,Niu, Xiaoda,Kozlowski, Joseph A.
scheme or table, p. 5286 - 5289 (2010/10/18)
We disclose further optimization of hydantoin TNF-α convertase enzyme (TACE) inhibitors. SAR with respect to the non-prime region of TACE active site was explored. A series of biaryl substituted hydantoin compounds was shown to have sub-nanomolar Ki
HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS
-
Page/Page column 113-114, (2008/06/13)
This invention relates to compounds of Formula (1) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.
